Fig. 9

(a) Composition and structure of the immune-activating Al-MOF-armored OVA (OVA@Al-MOFs), as well as the construction of a transport platform similar to a “Trojan Horse” (OVA@Al-MOFs/YCs). (b) The levels of expression of CD80 and MHC class II on RAW264.7 macrophages, as well as the quantities of released IL-6 and IL-1 in culture supernatants, in response to treatment with medium alone (Untreated Control), OVA, Al-MOFs, YCs, OVA@Al-MOFs, OVA@Al-MOFs/YCs, or LPS for 24 h. As a result of the oral administration of OVA@Al-MOFs/FITC-YCs to mice, the following are some schematic renderings and CLSM pictures of (c) lymph vessels, and (d) mesenteric lymph node (MLN): the route of transport. After oral treatment (e) with OVA@Al-MOFs/YCs at different dosage regimens and (f) with OVA, OVA@Al-MOFs, or OVA@Al-MOFs/YCs employing a three-dose oral vaccination schedule, OVA-specific S-IgA and IgG concentrations were assessed [129]